Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test
April 15, 2011
Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test
The company released results from studies of its six-protein diagnostic panel for lung cancer at this month's AACR meeting and this summer may take part in a 300-patient trial sponsored by the NCI's Early Detection Research Network.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Lung Cancer Study Highlights Current Limitations of MALDI Mass Spec
July 22, 2011 / ProteoMonitor - NCI's Early Detection Research Network Running Trials to Compare Biomarker-Based Cancer Diagnostics
April 22, 2011 / ProteoMonitor - Glycomics Firm Sialix Developing Auto Antibody-Based Tests for Breast, Colon, Prostate Cancers
April 29, 2011 / ProteoMonitor - GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor - UPCI Team Developing Lung Cancer Dx; Latest Entrant into Crowded, Growing Space
March 23, 2012 / ProteoMonitor